Overview

* BioLife Q3 2025 total revenue rises 31% yr/yr, driven by cell processing growth

* Cell processing revenue increases 33% yr/yr

* Company raises full-year 2025 revenue guidance to $95.0 mln - $96.0 mln

Outlook

* BioLife raises 2025 Cell Processing revenue guidance to $93 mln - $94 mln

* Company updates 2025 total revenue guidance to $95 mln - $96 mln

* BioLife expects 2025 gross margin in low-60% range, adjusted margin mid-60%

Result Drivers

* CELL PROCESSING DEMAND - Growth driven by strong demand from customers with commercially approved therapies

* ACCELERATED REVENUE - Biopreservation media revenue accelerated into Q3 2025 at a commercial customer's request

* BUSINESS RESTRUCTURING - Sale of evo subsidiary streamlined operations, focusing on cell processing

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 64.00%

Adjusted

Gross

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for BioLife Solutions Inc ( BLFS ) is $31.00, about 11.1% above its November 5 closing price of $27.57

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)